Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Agmatine sulfate

Agmatine Sulfate · also known as Agmatine, Agmatine, Super arginine, Endogenous neuromodulator

Agmatine is made from L-arginine by arginine decarboxylase. Animal and in-vitro (cell) studies suggest it can act on NMDA receptors, imidazoline receptors and nitric oxide synthase. Its oral absorption in humans, its brain exposure and the strength of its target effects are not established, so it cannot yet be treated as a proven neuroprotective agent.

Typical dose: 500–1500 mg/day in divided doses, taken on an empty stomach in the morning or before exercise/at bedtime
Absorption and forms: Agmatine dissolves easily in water. The route and extent of its absorption from the human gut have not been established, how much reaches the brain is unknown, and the degree to which it competes with dietary arginine for transport is also undetermined. So it cannot be claimed that taking it on an empty stomach boosts brain entry.

Clinical uses and human evidence

Peripheral neuropathy (numbness and tingling)

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Rosenberg 2020 · Nutrients · Open-label study · n=12 — Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study

Mechanisms of action

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

★★☆☆☆Mechanism evidence: grade CSecondary target

In rats, injected agmatine altered the firing of 5-HT neurons in the dorsal raphe nucleus and the expression of related receptors. But injection differs from oral supplementation, and effects at α2 and imidazoline receptors cannot be directly equated with regulation of monoamine synthesis or transport. Human effects are unknown.

References (1)
  1. 2025 · Rat study: injected agmatine altered dorsal raphe 5-HT neuron firing and related receptor expression

GABA and glutamate balance (inhibitory and excitatory tone)

★★☆☆☆Mechanism evidence: grade DPrimary target

In-vitro binding experiments suggest agmatine acts on polyamine-related sites of the NMDA receptor, opposing spermine-like enhancement. Blocking the channel directly requires higher concentrations, and there are no measurements of NMDA receptor occupancy in the human brain at usual oral doses.

References (2)
  1. Gibson et al. 2002 · In-vitro binding experiment in rat brain membranes: agmatine opposed spermine-like enhancement at NMDA receptor polyamine sites; direct inhibition of labeled binding required higher concentrations
  2. No direct study found in literature search · Conclusion: no reliable measurement of NMDA receptor occupancy or channel block in the human brain at usual oral doses

Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation

★★☆☆☆Mechanism evidence: grade DSecondary target

In isolated aorta experiments, agmatine affected eNOS phosphorylation, cGMP and relaxation responses, and brain eNOS expression changed in a rat ischemia model. However, these results do not establish endothelial coupling or vasodilation after oral intake, so “selective activation of eNOS” currently lacks support.

References (2)
  1. Santhanam et al. 2007 · Isolated rat aorta experiment: changes in eNOS phosphorylation, cGMP and relaxation were observed
  2. Mun et al. 2010 · Rat ischemia model: brain eNOS expression changed, but endothelial coupling and vasodilation after oral intake were not directly established

Safety and drug interactions

Use with levodopa-type Parkinson’s drugs only after a doctor has assessed it. People taking potent antidepressants should use it only under a doctor’s guidance, with the dose set by the doctor based on tolerance. Safety data for long-term use are limited.

With Levodopa Needs attention

Levodopa/benserazide (Madopar), carbidopa/levodopa (Sinemet)

May affect the action of dopaminergic drugs. Do not combine them without medical guidance.

Open in the interactive app ›